Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that the FDA has requested additional information regarding its CAR-T therapy, developed in partnership with Moffitt Cancer Center. This therapy, which targets the follicle stimulating hormone receptor (FSHR), is currently on clinical hold under the IND application until further details are provided by the FDA. Anixa expects MCC to submit the requested information promptly. The therapy is part of Anixa's broader oncology programs aimed at advancing innovative treatments for cancer.
Anixa Biosciences (NASDAQ: ANIX) announced progression to the next stage of its anti-viral therapy against Covid-19 following successful Proof of Concept (POC) animal studies. The studies evaluated two compounds alongside Remdesivir in Syrian Hamsters, showing no adverse effects and comparable efficacy. Anixa aims to optimize pharmacokinetics and potency of a chosen compound over the next four to five months. The company is also developing therapies for cancer and infectious diseases, including innovative vaccine technologies.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has announced an increase in its public offering of common stock, now totaling 4,285,715 shares at a price of $5.25 per share. This offering, set to close around March 25, 2021, could generate approximately $22.5 million in gross proceeds. The underwriter, H.C. Wainwright & Co., has an option for an additional 642,857 shares. Proceeds will support ongoing research, clinical trials, and potential acquisitions aligned with Anixa’s biotechnology focus on cancer and infectious diseases.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has announced a public offering of 1,904,762 shares at $5.25 per share, with expected gross proceeds of approximately $10 million. The offering is led by H.C. Wainwright & Co. and aims to fund ongoing research, clinical trials, and the development of new technologies. The offering's closing is anticipated around March 25, 2021, pending customary conditions. The registration of shares was effective as of June 21, 2019, and further details will be filed with the SEC.
Anixa Biosciences (NASDAQ: ANIX) has filed an IND application for its ovarian cancer CAR-T therapy with the U.S. FDA as of March 22, 2021. This therapy, developed under the leadership of Dr. Jose Conejo-Garcia, targets the follicle stimulating hormone receptor (FSHR), offering hope to women with recurrent ovarian cancer, a group with limited treatment options. The company holds an exclusive commercial license for this technology, with clinical trials to be conducted at Moffitt Cancer Center. Successful FDA clearance could initiate their second therapy in clinical trials.
Anixa Biosciences (NASDAQ: ANIX) announced the issuance of a European patent for its novel ovarian cancer vaccine technology, developed in collaboration with Cleveland Clinic. This patent, titled "Ovarian Cancer Vaccines," targets a specific protein that is present in pre-menopausal women and disappears after menopause. Dr. Amit Kumar emphasized the potential of this vaccine to significantly improve the poor five-year survival rates of ovarian cancer. The company also has a diverse portfolio, including vaccines for breast cancer and a COVID-19 therapeutic program.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology firm specializing in cancer and infectious disease treatments, announced that CEO Dr. Amit Kumar will present at the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The event, hosted by M Vest LLC and Maxim Group LLC, will feature discussions with industry leaders and presentations from various biotech firms. Anixa aims to highlight its innovative cancer therapeutics, including a unique CAR-T immunotherapy and vaccines for triple-negative breast cancer and ovarian cancer. More details are available at www.anixa.com.
Anixa Biosciences (NASDAQ: ANIX) announced the issuance of its first European patent for CAR-T cancer treatment technology, licensed from The Wistar Institute and developed with Moffitt Cancer Center. The patent, titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," provides protection within the European Union, complementing an existing U.S. patent. Anixa plans to file an IND application for its ovarian cancer CAR-T therapy by the end of Q1 2021, with clinical studies anticipated to start at Moffitt Cancer Center upon FDA clearance.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology firm focused on cancer and infectious disease treatments, announced Dr. Amit Kumar, CEO, will present at the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will provide an overview of Anixa's business and updates on its various programs. The session will be available on demand starting at 7:00 a.m. ET on March 9, and attendees can join one-on-one meetings with company management. Anixa develops innovative therapies, including cancer immunotherapies and vaccines.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has initiated animal testing for two proprietary compounds that exhibited potential in in vitro studies against COVID-19. CEO Dr. Amit Kumar stated that these compounds will soon be compared to Remdesivir, the only FDA-approved antiviral for COVID-19. The company anticipates completing this proof of concept study within weeks. The compounds target key enzymes of the virus, potentially remaining effective against emerging variants. Anixa aims for future human clinical trials following successful animal testing.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
